Tag: Amsterdam UMC
The Pharmaceutical Accountability Foundation welcomes the news that the Amsterdam UMC (Amsterdam University Medical Centers) has resumed supplying Dutch patients with the rare disease Cerebrotendinous Xanthomathosis (CTX) with pharmacy compounded chenodeoxycholic acid (CDCA).
This action became necessary after Leadiant Biosciences had increased the price of one CDCA capsule from €0,28...
Licensed under Creative Commons (CC BY-NC-SA 4.0), The Pharmaceutical Accountability Foundation 2022